Continuous (CONT-HAL), but not chronic and intermittent (INT-HAL), haloperidol (HAL) treatment potentiates amphetamine-induced Nur77 mRNA expression in the caudate-putamen. n's=24 in the SAL condition, and 9 per condition in remaining groups. CONT-HAL, group receiving 0.5 mg/kg/day haloperidol through minipump; INT-HAL, group receiving 0.05 mg/kg/day haloperidol through daily subcutaneous injection; SAL, combined control group receiving saline. *p<0.05 compared with SAL, #p<0.05 compared with VEH, αp<0.05 compared with INT-HAL. AMPH, amphetamine; DL, dorsolateral; DM, dorsomedial; VL, ventrolateral; VM, ventromedial.